The Diagnostic Value of Serum Golgi protein 73 (GP 73) as a Biomarker for Hepatocellular Carcinoma in Patients with HCV related Liver Cirrhosis
Nouran Mohamed Said;
Abstract
Hepatocellular carcinoma is one of the most common malignancies worldwide and the most common primary malignant tumor of the liver. It is the second leading cause of cancer related deaths in the world. It occurs most commonly on top of a cirrhotic liver which in Egypt is prevalence is due to chronic HCV infection.
When patients with obvious clinical symptoms come to the hospital for treatment, the HCC has already reached the mild to advanced stages and is usually large in size. Given the subsequent rapid growth and vascular invasion, the prognosis then is very poor.
Diagnosis of HCC at earlier stages, thus improves patient outcomes. Currently, the most commonly used methods for screening and diagnosing HCC are ultrasound imaging and serum α-fetoprotein (AFP) concentration measurements, but the diagnostic value of AFP is recently challenged due to its low sensitivity and specificity.
Golgi protein 73 (GP73, also known as Golph2), is a 400 amino acid, 73-kDa resident Golgi-specific membrane protein expressed by biliary epithelial cells in normal liver, and its expression is increased markedly in chronic liver diseases, especially in HCC cells. There have been studies reporting the use of serum GP73 as a serum marker for HCC, but the results are heterogeneous and even conflicting.
Although its functions are not completely understood , it’s assumed that it is responsible for decreasing the surface area of the Golgi apparatus and hence maintaining its integrity during cellular stress and many studies identified it as a potential biomarker for HCC.
The aim of this study is to determine the diagnostic value of serum Golgi protein 73 as a biomarker for HCC in patients with HCV related liver cirrhosis.
The study was conducted upon 75 subjects who were divided into three groups: group I included 25 patients with liver cirrhosis and hepatocellular carcinoma , group II included 25 patients with HCV related liver cirrhosis without HCC, group III had 25 healthy subjects as controls.
In this study, the serum levels of GP73 were highest in patients of group I with HCC compared to those with liver cirrhosis and the control groups.
Also GP73 values increased with tumor number ,over all size and also correlated with vascular invasion, where as those of AFP correlated with vascular invasion and didn’t correlate with tumor number or size.
At a cut off value 5, the diagnostic sensitivity and specificity of GP73 for selective detection of HCC over the cirrhotic group was 88% and 84.6% respectively.
At a cut off value 7.12, the diagnostic sensitivity and specificity of AFP for selective detection of HCC over the cirrhotic group was 76% and 76%
In conclusion, Golgi protein 73 can be used as a biomarker for hepatocellular carcinoma with a good diagnostic and prognostic value.
When patients with obvious clinical symptoms come to the hospital for treatment, the HCC has already reached the mild to advanced stages and is usually large in size. Given the subsequent rapid growth and vascular invasion, the prognosis then is very poor.
Diagnosis of HCC at earlier stages, thus improves patient outcomes. Currently, the most commonly used methods for screening and diagnosing HCC are ultrasound imaging and serum α-fetoprotein (AFP) concentration measurements, but the diagnostic value of AFP is recently challenged due to its low sensitivity and specificity.
Golgi protein 73 (GP73, also known as Golph2), is a 400 amino acid, 73-kDa resident Golgi-specific membrane protein expressed by biliary epithelial cells in normal liver, and its expression is increased markedly in chronic liver diseases, especially in HCC cells. There have been studies reporting the use of serum GP73 as a serum marker for HCC, but the results are heterogeneous and even conflicting.
Although its functions are not completely understood , it’s assumed that it is responsible for decreasing the surface area of the Golgi apparatus and hence maintaining its integrity during cellular stress and many studies identified it as a potential biomarker for HCC.
The aim of this study is to determine the diagnostic value of serum Golgi protein 73 as a biomarker for HCC in patients with HCV related liver cirrhosis.
The study was conducted upon 75 subjects who were divided into three groups: group I included 25 patients with liver cirrhosis and hepatocellular carcinoma , group II included 25 patients with HCV related liver cirrhosis without HCC, group III had 25 healthy subjects as controls.
In this study, the serum levels of GP73 were highest in patients of group I with HCC compared to those with liver cirrhosis and the control groups.
Also GP73 values increased with tumor number ,over all size and also correlated with vascular invasion, where as those of AFP correlated with vascular invasion and didn’t correlate with tumor number or size.
At a cut off value 5, the diagnostic sensitivity and specificity of GP73 for selective detection of HCC over the cirrhotic group was 88% and 84.6% respectively.
At a cut off value 7.12, the diagnostic sensitivity and specificity of AFP for selective detection of HCC over the cirrhotic group was 76% and 76%
In conclusion, Golgi protein 73 can be used as a biomarker for hepatocellular carcinoma with a good diagnostic and prognostic value.
Other data
| Title | The Diagnostic Value of Serum Golgi protein 73 (GP 73) as a Biomarker for Hepatocellular Carcinoma in Patients with HCV related Liver Cirrhosis | Other Titles | القيمة التشخيصية لبروتين جولجى 73 فى المصل كعلامة لسرطان الكبد فى المرضى المصابين بتليف الكبد الناتج عن فيروس (سى) | Authors | Nouran Mohamed Said | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.